[Drug-eluting stents in complex lesions].
Interventional cardiology has evolved tremendously over the past two years with the advent of drug-eluting stents. The RAVEL trial was the first randomized study conducted with sirolimus-eluting stents in a selected population of patients in whom a 0% rate of binary restenosis was achieved. The objective of the SIRIUS trial conducted in a more complex patient population was to test the efficacy of the sirolimus-eluting stent in high-risk settings such as coronary bifurcation lesions.
Lefèvre
T
T
Institut cardiovasculaire Paris-Sud, hôpital Jacques-Cartier, 6, avenue Noyer-Lambert, 91300 Massy, France. t.lefevre@icps.com.fr
D015906:Angioplasty, Balloon, Coronary; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors
D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus